Abstract
Background: The relation between cannabis use and psychotic disorders has been investigated extensively. A series of metaanalytic reviews reveal a robust association between cannabis use and the development of psychosis and schizophrenia. However, the actual impact of cannabis use in subjects at high clinical risk for psychosis (CHR) is still unclear.
Method: We conducted a systematic review of publications measuring the impact of cannabis use on CHR symptomatology and transition to a first psychotic episode.
Results: Of 729 potentially relevant papers, 11 met inclusion criteria. The results of these studies were mixed. In some studies, cannabis use was associated with more severe symptoms at baseline, increased pre-psychotic symptoms immediately after intoxication, and earlier onset of certain high-risk symptoms. In others, no significant association between cannabis use and baseline symptomatology was found. In one study, cannabis use was even significantly associated with a decrease in pre-psychotic negative symptoms, and with fewer symptoms of depression and anxiety. Four out of 5 studies reported no significant effect of cannabis use on transition to psychosis.
Conclusions: Cannabis use seems to provoke and enhance subclinical symptoms in CHR subjects. However, the results provide no consistent evidence for an association between cannabis use and transition to a first psychosis in CHR subjects.
Keywords: Prodrome, ultra high-risk, prodromal symptoms, cannabis, transition, psychosis
Current Pharmaceutical Design
Title:Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis
Volume: 18 Issue: 32
Author(s): Floor J. van der Meer, Eva Velthorst, Carin J. Meijer, Marise W.J. Machielsen and Lieuwe de Haan
Affiliation:
Keywords: Prodrome, ultra high-risk, prodromal symptoms, cannabis, transition, psychosis
Abstract: Background: The relation between cannabis use and psychotic disorders has been investigated extensively. A series of metaanalytic reviews reveal a robust association between cannabis use and the development of psychosis and schizophrenia. However, the actual impact of cannabis use in subjects at high clinical risk for psychosis (CHR) is still unclear.
Method: We conducted a systematic review of publications measuring the impact of cannabis use on CHR symptomatology and transition to a first psychotic episode.
Results: Of 729 potentially relevant papers, 11 met inclusion criteria. The results of these studies were mixed. In some studies, cannabis use was associated with more severe symptoms at baseline, increased pre-psychotic symptoms immediately after intoxication, and earlier onset of certain high-risk symptoms. In others, no significant association between cannabis use and baseline symptomatology was found. In one study, cannabis use was even significantly associated with a decrease in pre-psychotic negative symptoms, and with fewer symptoms of depression and anxiety. Four out of 5 studies reported no significant effect of cannabis use on transition to psychosis.
Conclusions: Cannabis use seems to provoke and enhance subclinical symptoms in CHR subjects. However, the results provide no consistent evidence for an association between cannabis use and transition to a first psychosis in CHR subjects.
Export Options
About this article
Cite this article as:
J. van der Meer Floor, Velthorst Eva, J. Meijer Carin, W.J. Machielsen Marise and de Haan Lieuwe, Cannabis Use in Patients at Clinical High Risk of Psychosis: Impact on Prodromal Symptoms and Transition to Psychosis, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884762
DOI https://dx.doi.org/10.2174/138161212802884762 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Disposable, Highly Sensitive Biosensing System: Determination of Haptoglobin as a Significant Acute Phase Biomarker
Current Analytical Chemistry Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity
Current Medicinal Chemistry Uric Acid and Oxidative Stress
Current Pharmaceutical Design Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery Opioids and Mechanical Ventilation
Current Drug Targets The Human Leukocyte Antigen Class III Haplotype Approach: New Insight in Alzheimer's Disease Inflammation Hypothesis
Current Alzheimer Research The Use of Tripeptides for Lead Discovery of 5-HT4 Receptor Ligands
Protein & Peptide Letters The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Seizures Secondary to Bupropion Misuse/Abuse: Three Cases
Adolescent Psychiatry A Piece of the ROCK: A Critical Role for Rho Kinases in the Nervous System
Current Neurovascular Research Neuroprotective Effects of a Glutathione Depletor in Rat Post-Ischemic Reperfusion Brain Damage
CNS & Neurological Disorders - Drug Targets Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Cholinesterase Inhibitors: From Weapons, to Pesticides, to Cognition Enhancing Drugs
Current Enzyme Inhibition Role of Grina/Nmdara1 in the Central Nervous System Diseases
Current Neuropharmacology Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Comparative Pharmacokinetics and Metabolism Studies in Lean and Diet- Induced Obese Mice: An Animal Efficacy Model for 11β -Hydroxysteroid Dehydrogenase Type 1 (11β -HSD1) Inhibitors
Drug Metabolism Letters Clinical Trials in Relapsing-Remitting Multiple Sclerosis /A New Proposal for Dealing with Basic Problems and Restrictions/
Reviews on Recent Clinical Trials